Prevascularized Retrievable Hybrid Implant to Enhance Function of Subcutaneous Encapsulated Islets
- 1 March 2022
- journal article
- research article
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 28 (5-6) , 212-224
Abstract
Replacement of pancreatic β-cells is one of the most promising treatment options for treatment of type 1 diabetes (T1D), however toxic immunosuppressive drugs are required. In this study, we aim to deliver allogeneic β-cell therapies without anti‐rejection drugs using a bioengineered hybrid device that contains microencapsulated β-cells inside 3D polycaprolactone (PCL) scaffolds printed using melt electrospin writing (MEW). Mouse β-cell (MIN6) pseudo-islets and QS-mouse islets are encapsulated in alginate microcapsules, without affecting viability and insulin secretion. Microencapsulated MIN6 cells are then seeded within 3D MEW scaffolds, and these hybrid devices implanted subcutaneously in streptozotocin-treated diabetic NOD/SCID and BALB/c mice. Similar to NOD/SCID mice, blood glucose levels (BGL) are lowered from 30.1 to 4.8 mmol/L in 25-41 days in BALB/c. In contrast, microencapsulated islets placed in pre-vascularized MEW scaffold 3 weeks after implantation in BALB/c mice normalize BGL (〈12 mmol/L) more rapidly, lasting for 60 - 105 days. The lowering of glucose levels is confirmed by an intraperitoneal glucose tolerance test. Vascularity within the implanted grafts is demonstrated and quantified by 3D-doppler ultrasound, with a linear increase over 4 weeks (r = 0.65). Examination of the device at 5 weeks shows inflammatory infiltrates of neutrophils, macrophages and B-lymphocytes on the MEW scaffolds but not on microcapsules, which have infrequent pro-fibrotic walling. In conclusion, we demonstrate the fabrication of an implantable and retrievable hybrid device for vascularization and enhancing the survival of encapsulated islets implanted subcutaneously in an allotransplantation setting without immunosuppression. This study provides proof-of-concept for the application of such devices for human use, however, will require modifications to allow translation to people with T1D.Keywords
This publication has 41 references indexed in Scilit:
- The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-co-ε-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic IsletsTransplantation, 2017
- A prevascularized subcutaneous device-less site for islet and cellular transplantationNature Biotechnology, 2015
- Strategy for clinical setting in intramuscular and subcutaneous islet transplantationDiabetes/Metabolism Research and Reviews, 2013
- Effect of prolonged gelling time on the intrinsic properties of barium alginate microcapsules and its biocompatibilityJournal of Microencapsulation, 2011
- Safety and Viability of Microencapsulated Human Islets Transplanted Into Diabetic HumansDiabetes Care, 2009
- Revascularization of Transplanted IsletsDiabetes, 2008
- The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in ratsBiomaterials, 2006
- Risks and side effects of islet transplantationCurrent Diabetes Reports, 2004
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- A COMPARATIVE STUDY OF TRANSPLANT SITES FOR ENDOCRINE TISSUE TRANSPLANTATION IN THE PIGImmunology & Cell Biology, 1986